3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms by Site
2
Carcinoma
2
Thoracic Neoplasms
1
Sarcoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma
1
Lung Neoplasms
1
Lung Diseases
1
Head and Neck Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
Pemetrexed
5
Carboplatin
5
Paclitaxel
3
osimertinib
2
Gemcitabine
2
pralsetinib
1
pembrolizumab
1
patritumab
1
napabucasin
1
atezolizumab
1
alectinib
1
Vinorelbine
1
Patient Reported Outcome Measures
1
Nivolumab
1
Metformin
1
Indocyanine Green
1
Erlotinib Hydrochloride
1
Cisplatin
1
Bevacizumab
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Thoracic Neoplasms
×
patritumab
×
Clear all
NCT02134015
2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3
Terminated
145 enrolled
20 charts